Csop Hang Seng Tech Index ETF(03033.HK) rose 2.67% to HKD 5.000
Newtimespace News, as of 09:55 on May 7, Csop Hang Seng Tech Index ETF(03033.HK) was quoted at HKD 5.000, up 2.67%. The ETF opened at HKD 4.956, with a high of HKD 5.005 and a low of HKD 4.956. The latest trading volume was 103 million units, with a turnover of HKD 512 million, and a turnover rate of 0.58%. The latest NAV per unit is HKD 4.862, with a premium rate of 0.16%. The asset size is approximately HKD 85.976 billion, and the total issuance is 17.682 billion units.
Csop Hang Seng Tech Index ETF(03033.HK) closely tracks the performance of the Hang Seng Tech Index. The index is compiled and published by Hang Seng Indexes Company Limited, aiming to reflect the overall performance of the most representative technology companies listed in Hong Kong. The index is calculated using the market capitalization weighting method and covers 30 renowned technology companies, including Alibaba, Tencent Holdings, Meituan, Xiaomi Corporation, and Kuaishou Technology. It broadly covers high-growth new economy sectors such as e-commerce, social media, online gaming, fintech, smart logistics, and new energy vehicles.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment